Format

Send to

Choose Destination
Neurosurg Clin N Am. 2012 Apr;23(2):323-9, ix-x. doi: 10.1016/j.nec.2012.01.008. Epub 2012 Feb 18.

Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.

Author information

1
Department of Neurological Surgery, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th Street, Box 99, New York, NY 10021, USA.

Abstract

Glioblastoma multiforme constitutes the most common primary brain tumor and carries a grim prognosis for patients treated with conventional therapy including surgery, radiation therapy, and chemotherapy. There has been a recent revival of selective intra-arterial delivery of targeted agents for the treatment of glioblastoma multiforme. Because these agents are less toxic and their delivery leads to a higher tumor-drug concentration, this combination may provide a better outcome in patients with high-grade glioma. This article discusses early experiences in patients who received superselective intra-arterial cerebral infusion of bevacizumab, cetuximab, and temozolamide after blood-brain barrier disruption with mannitol.

PMID:
22440875
DOI:
10.1016/j.nec.2012.01.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center